FDA advisory vote boosts access hopes for peptide supporters, but compounding stays illegal pending rulemaking.
The FDA's Pharmacy Compounding Advisory Committee (PCAC) spent 2 days in late July voting on 7 peptides pulled from compounding in 2023. Six passed. One didn't.1 The headlines since have mostly said some version of "FDA Approves Peptides," which is incorrect in a way that matters for how I counsel patients this week.
Here's what actually happened and why the gap between the vote and the headline is the whole story right now.
BPC-157, KPV, and TB-500 each cleared on an identical 8-6 split with 1 abstention. MOTS-c passed 7-5 with 2 abstentions, the tightest margin of the 4 peptides reviewed on day 1.2 Day 2 brought the only rejection: emideltide failed 6-7, while epitalon and semax both passed.3 Six of 7 made it through. None of them are legal to compound yet.
That distinction is not a technicality. A PCAC recommendation is advisory. FDA leadership must decide whether to act and make any actual change to the 503A Bulks List requires formal rulemaking, the kind of process that runs for months, sometimes longer.4 Nothing a patient can legally get from a compounding pharmacy today changed because of this vote. What changed is the direction the wind is blowing.
It is worth knowing why this process felt rushed: 8 temporary members were added to the committee shortly before the meeting, and that bloc voted yes as a group on day 1.5 The FDA's own scientific staff had recommended against adding any of the 7 peptides, citing thin controlled trial data and unresolved impurity and immunogenicity questions.2 The committee voted past its own agency's scientists. That's unusual, and it's part of why this is getting so much attention beyond the peptide-specific trade press.
Nothing is legal today that wasn't legal 2 weeks ago. That's the first sentence out of my mouth every time this comes up. Then I walk through 3 categories, because most of the confusion I'm seeing comes from patients collapsing them into 1.
I've had a few patients treat the vote itself as proof these peptides work. It isn't. BPC-157's human evidence is limited to a handful of small pilot studies. TB-500 has no completed human randomized controlled trials.3 A favorable committee vote reflects a judgment call about access and gray-market risk, not a verdict on efficacy. Patients deserve to hear that distinction plainly, not have it softened.
If the FDA does move forward with rulemaking, the practical questions I'll be tracking are the same ones I'd tell any pharmacist to track: whether the compounding pharmacy carries Pharmacy Compounding Accreditation Board accreditation, whether they're meeting USP <795> and <797> standards, and whether they can produce a certificate of analysis with third-party purity verification.4 None of that matters yet, because none of these peptides can legally be compounded today. But the infrastructure question is worth having an answer to before the regulatory timeline catches up, not after.
The committee is scheduled to reconvene before the end of February 2027 to review 5 more peptides, so this isn't a one-time story.5 Patient interest is going to keep outpacing the slower administrative process behind it, which means the conversation around legality is one I expect to keep having for a while.
